Ghent University, and Department of Neurology, Ghent University Hospital, Ghent, Belgium.
Clin Auton Res. 2011 Oct;21(5):347-51. doi: 10.1007/s10286-011-0118-6. Epub 2011 Mar 8.
Used in the diagnosis of Horner's syndrome, apraclonidine 1% dilatates the involved eye due to denervation supersensitivity. Recent literature suggests that in healthy volunteers, apraclonidine provokes a mild miotic effect. Since the comparison of both the pathologic and the non-pathologic eye is important, we wanted to further investigate the effect of apraclonidine on the healthy eye. By measuring the effect on the pupil intermittently over a few hours, we tried to determine the best moment for evaluation after instillation with apraclonidine. Therefore, the effect of apraclonidine on pupillary parameters was investigated in 14 healthy volunteers.
Infrared pupillography was used to measure the scotopic pupil diameter and the dynamic pupil responses to light. The first measurements were performed prior to instillation of apraclonidine. Measurements were retaken 30, 60, 90, 120, 180, 240, 300 and 360 min after random instillation of one eye with one drop of 1% apraclonidine.
The anisocoria after dark adaptation and at minimum pupil diameter differed significantly for the measurements obtained 30 and 60 min after instillation with apraclonidine. The eye with apraclonidine drops showed relative miosis and an increased amplitude of constriction to light. No significant influence was found on the latency, the constriction velocity and redilation velocity.
Instillation of apraclonidine 1% in healthy subjects causes relative miosis, which is most pronounced after 30-60 min. The amplitude of constriction to light also differs significantly. The relative miotic effect of apraclonidine could be explained by the α-2 receptor agonistic effect which is more pronounced than the α-1 agonistic effect in healthy subjects. In patients with Horner's syndrome, the α-1 agonistic effect will dominate because of the supersensitivity of the α-1 receptors, resulting in relative mydriasis. These findings stress the necessity to instill the unaffected eye in diagnosing a suspected Horner's pupil.
用于霍纳综合征的诊断,1%盐酸阿可乐定散瞳由于去神经超敏。最近的文献表明,在健康志愿者中,阿可乐定引起轻微的缩瞳效应。由于比较病变眼和非病变眼很重要,我们想进一步研究阿可乐定对健康眼的影响。通过在几个小时内间歇性测量瞳孔的影响,我们试图确定滴注阿可乐定后评估的最佳时刻。因此,我们在 14 名健康志愿者中研究了阿可乐定对瞳孔参数的影响。
采用红外瞳孔描记术测量暗适应瞳孔直径和动态瞳孔对光的反应。第一次测量是在滴注阿可乐定之前进行的。在随机滴注一只眼一滴 1%阿可乐定后 30、60、90、120、180、240、300 和 360 分钟后,再次进行测量。
暗适应后和最小瞳孔直径的瞳孔不等,在滴注阿可乐定后 30 和 60 分钟的测量值差异有统计学意义。滴注阿可乐定的眼出现相对的瞳孔缩小和光收缩幅度增加。潜伏期、收缩速度和再扩张速度无明显影响。
在健康受试者中滴注 1%阿可乐定会引起相对的瞳孔缩小,在 30-60 分钟后最为明显。光收缩幅度也有显著差异。阿可乐定的相对缩瞳作用可以用其 α-2 受体激动作用来解释,在健康受试者中,这种作用比 α-1 受体激动作用更为明显。在霍纳综合征患者中,由于 α-1 受体的超敏性,α-1 受体激动作用占主导地位,导致相对的散瞳。这些发现强调了在诊断可疑的霍纳氏瞳孔时,有必要滴注未受影响的眼睛。